Fig. 2: PANDAR reduces cisplatin sensitivity in chemosensitive ovarian cancer cells. | Cell Death & Disease

Fig. 2: PANDAR reduces cisplatin sensitivity in chemosensitive ovarian cancer cells.

From: The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation

Fig. 2

a CCK-8 assay of cell viability in A2780-PANDAR-knockdown cells (shPANDAR) after treated with indicated doses of cisplatin for 24 h, ctrl shRNA cells serve as controls. b Cell survival rate was measured from a through three independent experiments. c The half maximal inhibitory concentration (IC50) was calculated from b using GraphPad 6.2 software. d Cell viability in HO-8910PM-PANDAR cells after treated with indicated doses of cisplatin for 24 h via CCK-8 analysis, HO-8910PM-Vector cells serve as controls. e Cell survival rate was calculated from d through three independent experiments. f The half maximal inhibitory concentration (IC50) was calculated from e using GraphPad 6.2 software. g Flow cytometry assay (FCM) of cell apoptosis in chemosensitive HO8910PM-PANDAR-overexpressing cells with or without a 24-h treatment of 20 μmol/L cisplatin. Early apoptotic population in the lower right gate is characterized with Annexin V (+) and PI (−), and late apoptotic population in the upper right gate is characterized with Annexin V (+) and PI (+). h Protein expression of Bax and Bcl-2 in HO-8910PM-PANDAR overexpressing cells with a 12-h treatment of 20 μM cisplatin, Non-treated Vector cells serve as controls. Vector and ctrl shRNA groups are normalized to 1. Data presents the mean ± S.D. *p < 0.05, **p < 0.01, ****p < 0.0001, ns non-significant, two-tailed Student’s t-test. n = 3 independent experiments. A-V Annexin V

Back to article page